Cochrane · systematic review · CD009865
Celecoxib for osteoarthritis
Puljak, L, Marin, A, Vrdoljak, D, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 14.3%Very low 6 · 42.9%Low 1 · 7.1%Moderate 3 · 21.4%High 2 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Celecoxib versus placebo for osteoarthritis
Population: osteoarthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain Celecoxib vs placebo | no estimate extracted | 4 studies · 1622 participants | High |
Physical function Celecoxib vs placebo | no estimate extracted | 4 studies · 1622 participants | High |
Quality of life Celecoxib vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number withdrawn due to adverse events Celecoxib vs placebo | Peto OR 0.99 [0.85, 1.15] | 24 studies · 10996 participants | Moderate Downgraded: risk of bias, imprecision |
Number experiencing any serious adverse events Celecoxib vs placebo | Peto OR 0.95 [0.66, 1.36] | 22 studies · 10926 participants | Very low Downgraded: risk of bias, imprecision |
Number experiencing gastro‐intestinal events (perforation, ulcer, bleeds) Celecoxib vs placebo | Peto OR 1.91 [0.24, 14.9] | 8 studies · 3263 participants | Very low Downgraded: risk of bias, imprecision |
Number experiencing cardiovascular events (myocardial infarction, stroke) Celecoxib vs placebo | Peto OR 3.4 [0.73, 15.88] | 4 studies · 2112 participants | Very low Downgraded: risk of bias, imprecision |
Celecoxib versus tNSAIDs for osteoarthritis
Population: osteoarthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pain Celecoxib vs tNSAIDs | no estimate extracted | 2 studies · 1180 participants | Moderate Downgraded: risk of bias, imprecision, publication bias |
Physical function Celecoxib vs tNSAIDs | no estimate extracted | 1 study · 264 participants | Moderate Downgraded: risk of bias, imprecision, publication bias |
Quality of life Celecoxib vs tNSAIDs | no estimate extracted | 0 studies · 0 participants | Ungraded |
Number withdrawn due to adverse events Celecoxib vs tNSAIDs | Peto OR 0.97 [0.74, 1.27] | 8 studies · 3150 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Number experiencing any serious adverse events Celecoxib vs tNSAIDs | Peto OR 0.92 [0.66, 1.28] | 5 studies · 2404 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Number experiencing gastro‐intestinal events (perforation, ulcer, bleeds) Celecoxib vs tNSAIDs | Peto OR 0.61 [0.15, 2.43] | 4 studies · 1755 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Number experiencing cardiovascular events (myocardial infarction, stroke) Celecoxib vs tNSAIDs | Peto OR 0.47 [0.17, 1.25] | 1 study · 916 participants | Very low Downgraded: risk of bias, imprecision, publication bias |